nach oben

Digestive Diseases and Sciences

Erschienen in:

22.01.2024 | Review

Pantoprazole and Vonoprazan Performed Well in Preventing Peptic Ulcer Recurrence in Low-Dose Aspirin Users

verfasst von: Haoyu An, Jing Chen, Shicong Li, Anni Chen

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Low-dose aspirin (LDA) administration is associated with an elevated risk of recurring peptic ulcer (PU) and gastrointestinal (GI) hemorrhage.

Aims

This systematic review and Bayesian network meta-analysis aimed to comprehensively assess the effectiveness of diverse medications in preventing the recurrence of PU and GI hemorrhage in patients with a history of PU receiving long-term LDA therapy.

Methods

This systematic review and network meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and was registered on PROSPERO (CRD42023406550). We searched relevant studies in main databases from inception to March 2023. All statistical analyses were performed using R (version 4.1.3), with the “Gemtc” (version 1.0-1) package. The pooled risk ratio (RR), corresponding 95% credible interval (95% CrI), and the surface under the cumulative ranking curve (SUCRA) were calculated.

Results

11 Randomized clinical trials (RCTs) were included. The analysis underscored pantoprazole was the most efficacious for reducing the risk of PU recurrence (RR [95% CrI] = 0.02 [0, 0.28]; SUCRA: 90.76%), followed by vonoprazan (RR [95% CrI] = 0.03 [0, 0.19]; SUCRA: 86.47%), comparing with the placebo group. Pantoprazole also performed well in preventing GI hemorrhage (RR [95% CrI] = 0.01[0, 0.42]; SUCRA: 87.12%) compared with Teprenone.

Conclusions

For patients with a history of PU receiving LDA, pantoprazole and vonoprazan might be the optimal choices to prevent PU recurrence and GI hemorrhage.

Graphical Abstract

Nur mit Berechtigung zugänglich

Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (Lond, Engl) 2009;373:1849–1860.CrossRef

Guirguis-Blake JM, Evans CV, Senger CA, O’Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:804–813.PubMedCrossRef

Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2022;327:1585–1597.PubMedCrossRef

Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2019;140:e596–e646.PubMedPubMedCentral

Collet JP, Thiele H, Barbato E et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289–1367.PubMedCrossRef

Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227–3337.PubMedCrossRef

Davidson KW, Barry MJ, Mangione CM et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement. JAMA 2022;327:1577–1584.PubMedCrossRef

Sundström J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study. Circulation 2017;136:1183–1192.PubMedCrossRef

Nelson MR, Polekhina G, Woods RL et al. Safety of ceasing aspirin used without a clinical indication after age 70 years: a subgroup analysis of the ASPREE Randomized Trial. Ann Intern Med 2022;175:761–764.PubMedPubMedCentralCrossRef

10.

Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA 2019;321:277–287.PubMedPubMedCentralCrossRef

11.

Takeuchi K, Yasuhiro T, Asada Y, Sugawa Y. Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats. Digestion 1998;59:298–307.PubMedCrossRef

12.

Feldman M, Shewmake K, Cryer B. Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 2000;279:G1113–G1120.PubMedCrossRef

13.

Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000–1016.PubMedCrossRef

14.

Kang DO, An H, Park GU et al. Cardiovascular and bleeding risks associated with nonsteroidal anti-inflammatory drugs after myocardial infarction. J Am Coll Cardiol 2020;76:518–529.PubMedCrossRef

15.

Abraham NS, Hartman C, Richardson P, Castillo D, Street RL Jr, Naik AD. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. Circulation 2013;128:1869–1877.PubMedCrossRef

16.

Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033–2038.PubMedCrossRef

17.

Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med 2018;378:2506–2516.PubMedCrossRef

18.

Taha AS. Vonoprazan, aspirin and NSAIDs: new era in acid inhibition and gastroprotection. Gut 2018;67:995–996.PubMedCrossRef

19.

Kawai T, Oda K, Funao N et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018;67:1033–1041.PubMedCrossRef

20.

Iwakiri R, Higuchi K, Kato M et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther 2014;40:780–795.PubMedCrossRef

21.

Sanuki T, Fujita T, Kutsumi H et al. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. J Gastroenterol 2012;47:1186–1197.PubMedCrossRef

22.

Suemasu S, Tanaka K, Namba T et al. A role for HSP70 in protecting against indomethacin-induced gastric lesions. J Biol Chem 2009;284:19705–19715.PubMedPubMedCentralCrossRef

23.

Hirakawa T, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 1996;111:345–357.PubMedCrossRef

24.

Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T, Okabe S. Effects of the antiulcer drug geranylgeranylacetone on aspirin-induced gastric ulcers in rats. Jpn J Pharmacol 1982;32:299–306.PubMedCrossRef

25.

Du YQ, Su T, Hao JY et al. Gastro-protecting effect of gefarnate on chronic erosive gastritis with dyspeptic symptoms. Chin Med J 2012;125:2878–2884.PubMed

26.

Hartling L, Vandermeer B, Fernandes RM. Systematic reviews, overviews of reviews and comparative effectiveness reviews: a discussion of approaches to knowledge synthesis. Evidence-Based Child Health 2014;9:486–494.PubMedCrossRef

27.

Szabó IL, Mátics R, Hegyi P et al. PPIs prevent aspirin-induced gastrointestinal bleeding better than H2RAs. A systematic review and meta-analysis. JGLD 2017;26:395–402.PubMedCrossRef

28.

Mo C, Sun G, Wang YZ, Lu ML, Yang YS. PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: systematic review and meta-analysis. PLoS ONE 2015;10:e0131558.PubMedPubMedCentralCrossRef

29.

Tian J, Gao Y, Zhang J et al. Progress and challenges of network meta-analysis. J Evid Based Med 2021;14:218–231.PubMedCrossRef

30.

Nikolakopoulou A, Mavridis D, Salanti G. Planning future studies based on the precision of network meta-analysis results. Stat Med 2016;35:978–1000.PubMedCrossRef

31.

Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–784.PubMedCrossRef

32.

An H, Li Y. Prevention of peptic ulcer recurrence in low-dose aspirin users with different treatment regimens: a Bayesian network meta-analysis. 2023.

33.

Scheiman JM, Devereaux PJ, Herlitz J et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart (Br Cardiac Soc) 2011;97:797–802.CrossRef

34.

Sugano K, Choi M-G, Lin J-T et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut 2014;63:1061–1068.PubMedCrossRef

35.

Goldstein JL, Huang B, Amer F, Christopoulos NG. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 2004;26:1637–1643.PubMedCrossRef

36.

Sugano K, Matsumoto Y, Itabashi T et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 2011;46:724–735.PubMedPubMedCentralCrossRef

37.

Chan FK, Kyaw M, Tanigawa T et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology 2017;152:105–10.e1.PubMedCrossRef

38.

Ng FH, Wong SY, Lam KF et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010;138:82–88.PubMedCrossRef

39.

Tseng ZF, Hsu PI, Peng NJ et al. Omeprazole vs famotidine for the prevention of gastroduodenal injury in high-risk users of low-dose aspirin: a randomized controlled trial. J Chin Med Assoc 2021;84:19–24.PubMedCrossRef

40.

Li DK, Ong SY, Hughes ML et al. Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. Aliment Pharmacol Ther 2023;57:94–102.PubMedCrossRef

41.

Guo CG, Cheung KS, Zhang F et al. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study. Gut 2020;69:445–452.PubMedCrossRef

42.

Cea Soriano L, Lanas A, Soriano-Gabarró M, García Rodríguez LA. Incidence of upper and lower gastrointestinal bleeding in new users of low-dose aspirin. Clin Gastroenterol Hepatol 2019;17:887–95.e6.PubMedCrossRef

43.

Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17–25.PubMedCrossRef

44.

Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 1993;15:314–320.PubMed

45.

Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991;32:77–83.PubMedPubMedCentralCrossRef

46.

Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet (Lond, Engl) 1996;348:1413–1416.CrossRef

47.

Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ (Clin Res Ed) 1996;312:1563–1566.CrossRef

48.

Weideman RA, Kelly KC, Kazi S et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology 2004;127:1322–1328.PubMedCrossRef

49.

Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108:294–307.PubMedCrossRef

50.

Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004;126:7800–7811.PubMedCrossRef

51.

Komazawa Y, Adachi K, Mihara T et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol 2003;18:678–682.PubMedCrossRef

52.

Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118:S9-31.PubMedCrossRef

53.

Garnock-Jones KP. Vonoprazan: first global approval. Drugs 2015;75:439–443.PubMedCrossRef

54.

Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438–22446.PubMedCrossRef

55.

Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion–tolerance and rebound. Aliment Pharmacol Ther 1997;11:1013–1018.PubMedCrossRef

56.

Waldum HL, Hauso Ø, Fossmark R. The regulation of gastric acid secretion - clinical perspectives. Acta Physiol (Oxf) 2014;210:239–256.PubMedCrossRef

57.

Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol 2004;94:106–111.PubMedCrossRef

58.

Ehrlich A, Lücker PW, Wiedemann A, Sander P, Huber R, Mascher H. Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find Exp Clin Pharmacol 1999;21:47–51.PubMedCrossRef

59.

Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discovery 2003;2:132–139.PubMedCrossRef

60.

Feldman M. Prostaglandins and gastric ulcers: from seminal vesicle to misoprostol (Cytotec). Am J Med Sci 1990;300:116–132.PubMedCrossRef

61.

Chen MC, Amirian DA, Toomey M, Sanders MJ, Soll AH. Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase. Gastroenterology 1988;94:1121–1129.PubMedCrossRef

62.

Katoh Y, Tanaka M, Kawashima H. Protective effects of teprenone and gefarnate against taurocholate/hydrochloric acid-induced acute gastric mucosal lesions in rats. Nihon yakurigaku zasshi Folia pharmacologica Japonica 1998;112:323–331.PubMedCrossRef

63.

Kim H, Kim KH. Effects of a nitric oxide donor and nitric oxide synthase inhibitors on acid secretion of isolated rabbit gastric glands. Pharmacology 1996;53:331–339.PubMedCrossRef

64.

Nishida K, Ohta Y, Ishiguro I. Preventive effect of teprenone on stress-induced gastric mucosal lesions and its relation to gastric mucosal constitutive nitric oxide synthase activity. Pharmacol Res 1999;39:325–332.PubMedCrossRef

65.

Matok I, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012;57:699–705.PubMedCrossRef

66.

Bianchi Porro G, Parente F. Side effects of anti-ulcer prostaglandins: an overview of the worldwide clinical experience. Scand J Gastroenterol 1989;164:224–229 (discussion 9-31).CrossRef

67.

Arora G, Singh G, Triadafilopoulos G. Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice. Clin Gastroenterol Hepatol 2009;7:725–735.PubMedCrossRef

68.

Klatte DCF, Gasparini A, Xu H et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology 2017;153:702–710.PubMedCrossRef

69.

Lee SW, Ha EK, Yeniova A et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021;70:76–84.PubMedCrossRef

70.

Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med 2017;177:784–791.PubMedPubMedCentralCrossRef

71.

Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther 2016;168:12–22.PubMedCrossRef

72.

Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil 2018;24:334–344.PubMedPubMedCentralCrossRef

73.

Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:2217–2228.PubMedPubMedCentralCrossRef

74.

Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol 2016;111:949–956.PubMedCrossRef

Titel: Pantoprazole and Vonoprazan Performed Well in Preventing Peptic Ulcer Recurrence in Low-Dose Aspirin Users
verfasst von: Haoyu An
Jing Chen
Shicong Li
Anni Chen
Publikationsdatum: 22.01.2024
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 3/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-023-08233-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusions

Graphical Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Gastroenterological Education: Do Digital Data Depositories Make a Difference?

VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis

Telehepatology Satisfaction Is Associated with Ethnicity: The Real-World Experience of a Vulnerable Population with Fatty Liver Disease

To Perform or Not to Perform Sphincterotomy in Hilar Malignant Strictures?

Starting from the Bottom: Unraveling Obesity’s Impact on Anorectal Function